---
title: Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML:a randomized,
  placebo-controlled study by the ALLG
date: '2023-08-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37647654/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20230831181054&v=2.17.9.post6+86293ac
source: Blood
description: Sorafenib maintenance improves outcome after hematopoietic cell transplant
  (HCT) for patients with FLT3-ITD acute myeloid leukemia (AML). Although promising
  outcomes have been reported for sorafenib plus intensive chemotherapy, randomized
  data are limited. This placebo-controlled, phase 2 study (ACTRN12611001112954) randomized
  102 patients 18-65 years (2:1) to sorafenib vs placebo (days 4-10) combined with
  intensive induction; idarubicin 12mg/m2 days 1-3 plus cytarabine 1.5g/m2 twice daily
  ...
disable_comments: true
---
Sorafenib maintenance improves outcome after hematopoietic cell transplant (HCT) for patients with FLT3-ITD acute myeloid leukemia (AML). Although promising outcomes have been reported for sorafenib plus intensive chemotherapy, randomized data are limited. This placebo-controlled, phase 2 study (ACTRN12611001112954) randomized 102 patients 18-65 years (2:1) to sorafenib vs placebo (days 4-10) combined with intensive induction; idarubicin 12mg/m2 days 1-3 plus cytarabine 1.5g/m2 twice daily ...